Reactive astrocyte nomenclature, definitions, and future directions

Carole Escartin*, Elena Galea*, András Lakatos, James P. O’Callaghan, Gabor C. Petzold, Alberto Serrano-Pozo, Christian Steinhäuser, Andrea Volterra, Giorgio Carmignoto, Amit Agarwal, Nicola J. Allen, Alfonso Araque, Luis Barbeito, Ari Barzilai, Dwight E. Bergles, Gilles Bonvento, Arthur M. Butt, Wei Ting Chen, Martine Cohen-Salmon, Colm CunninghamBenjamin Deneen, Bart De Strooper, Blanca Díaz-Castro, Cinthia Farina, Marc Freeman, Vittorio Gallo, James E. Goldman, Steven A. Goldman, Magdalena Götz, Antonia Gutiérrez, Philip G. Haydon, Dieter H. Heiland, Elly M. Hol, Matthew G. Holt, Masamitsu Iino, Ksenia V. Kastanenka, Helmut Kettenmann, Baljit S. Khakh, Schuichi Koizumi, C. Justin Lee, Shane A. Liddelow, Brian A. MacVicar, Pierre Magistretti, Albee Messing, Anusha Mishra, Anna V. Molofsky, Keith K. Murai, Christopher M. Norris, Seiji Okada, Stéphane H.R. Oliet, João F. Oliveira, Aude Panatier, Vladimir Parpura, Marcela Pekna, Milos Pekny, Luc Pellerin, Gertrudis Perea, Beatriz G. Pérez-Nievas, Frank W. Pfrieger, Kira E. Poskanzer, Francisco J. Quintana, Richard M. Ransohoff, Miriam Riquelme-Perez, Stefanie Robel, Christine R. Rose, Jeffrey D. Rothstein, Nathalie Rouach, David H. Rowitch, Alexey Semyanov, Swetlana Sirko, Harald Sontheimer, Raymond A. Swanson, Javier Vitorica, Ina Beate Wanner, Levi B. Wood, Jiaqian Wu, Binhai Zheng, Eduardo R. Zimmer, Robert Zorec, Michael V. Sofroniew*, Alexei Verkhratsky*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

1434 Scopus citations

Abstract

Reactive astrocytes are astrocytes undergoing morphological, molecular, and functional remodeling in response to injury, disease, or infection of the CNS. Although this remodeling was first described over a century ago, uncertainties and controversies remain regarding the contribution of reactive astrocytes to CNS diseases, repair, and aging. It is also unclear whether fixed categories of reactive astrocytes exist and, if so, how to identify them. We point out the shortcomings of binary divisions of reactive astrocytes into good-vs-bad, neurotoxic-vs-neuroprotective or A1-vs-A2. We advocate, instead, that research on reactive astrocytes include assessment of multiple molecular and functional parameters—preferably in vivo—plus multivariate statistics and determination of impact on pathological hallmarks in relevant models. These guidelines may spur the discovery of astrocyte-based biomarkers as well as astrocyte-targeting therapies that abrogate detrimental actions of reactive astrocytes, potentiate their neuro- and glioprotective actions, and restore or augment their homeostatic, modulatory, and defensive functions.

Original languageEnglish
Pages (from-to)312-325
Number of pages14
JournalNature Neuroscience
Volume24
Issue number3
DOIs
StatePublished - Mar 2021

Funding

FundersFunder number
Centers for Disease Control and Prevention
Centre National de la Recherche Scientifique
Commissariat à l'Énergie Atomique et aux Énergies Alternatives
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung31003A 173124/1, 160620, 173124
National Institute of Mental HealthR01MH104701
Synapsis Foundation Heidi Seiler-Stiftung2018-PI01
SNSF NCCR51NF40-160620
Alzheimer's AssociationAACF-17-524184
National Institute on AgingR56AG060974, RF1AG061774, R01AG056998, R01AG066171, K08AG064039
Japan Society for the Promotion of Science19H04746
Deutsche Forschungsgemeinschaft722053 EU-GliaPhD, STE 552/5, STE 552/4, SPP1757
National Institute of Neurological Disorders and StrokeR01NS036692, R01NS105807, R01NS102807, R01NS084030
Generalitat de Catalunya2017-SGR547
Bundesministerium für Bildung und Forschung16GW0182, 16GW0182 CONNEXIN
Horizon 2020 Framework Programme722053

    Fingerprint

    Dive into the research topics of 'Reactive astrocyte nomenclature, definitions, and future directions'. Together they form a unique fingerprint.

    Cite this